openPR Logo
Press release

Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-acting Biosimilars, and Premixed Biosimilars

08-27-2018 04:31 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Insulin Biosimilars Market, by Biosimilar Type Rapid-acting

Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American Society For Metabolic And Bariatric Surgery report, obesity was a major independent risk factor for developing the disease, and more than 90% of type 2 diabetics population are overweight or obese due to growing adoption of unhealthy lifestyle. Insulin is distributed and manufactured by small number of multinational companies in emerging economies, beyond the established biosimilar manufactures, and a handful of small players are developing insulin manufacturing capacities based on modern biotechnological methods in turn, boosting growth of the insulin biosimilars market size.

Get The Holistic SAMPLE Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1750

Insulin Biosimilars Market – Dynamics

Increasing number of manufacturers are developing biosimilar insulin to provide clinical aid that are similar to current insulin analogs at the more affordable price. Moreover, the patents of several insulin manufacturing companies are soon expected to lose patent protection, For instance, LEVEMIR an Insulin detemir by Novo Nordisk is going to lose its patent rights in year 2019, which is influencing numerous pharmaceutical key manufacturers to develop alternatives to patents, referred as biosimilar. The low cost of biosimilar insulin for diabetes treatment and effectiveness is helping treat patients suffering from diabetes mellitus. Companies are also focusing on developing medical devices that allows for less painful and safe delivery of the biosimilar insulin treatment, which in turn, is boosting market growth. Government agencies are focusing on the endorsement of insulin biosimilar by funding research and development. Furthermore, rising geriatric population across the globe and increasing demand for rapid-acting insulin analogues is boosting growth of the insulin biosimilar market. For instance, according to a consensus report published in 2012 American Diabetes Association, showed over 25% of the U.S. population aged ≥65 years suffered from diabetes.

However, critical regulatory requirements for approval of insulin biosimilar products besides strong opposition from branded manufactures regarding patent rights, high cost of production, manufacturing complexities, and various safety concerns associated with changes in drug formulations pose as factors hampering growth of the insulin biosimilars market.

Insulin Biosimilars Market – Regional Insights

On the basis of region, the global insulin biosimilars market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America leads the global insulin biosimilar market, owing to rising geriatric population and high prevalence of diabetes-related disorders in the region. Moreover, government support for diabetes-free states is accelerating growth of the insulin biosimilar market in North America. For instance, Centers for Disease Control and Prevention (CDC) runs a National Diabetes Prevention Program in various U.S states.

Download The PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1750

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website:https://www.coherentwire.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-acting Biosimilars, and Premixed Biosimilars here

News-ID: 1204153 • Views:

More Releases from Coherent Market Insights

Future Scope of Sulfone Polymer Market Set for Rapid Growth, Demand, Scope, Size, Share, Forecast 2032
Future Scope of Sulfone Polymer Market Set for Rapid Growth, Demand, Scope, Size …
Sulfone Polymer Market is estimated to be valued at USD 1.2 Mn in 2025 and is expected to reach USD 2.2 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 9.05% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Sulfone Polymer Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth factors, and
Internal Nasal Dilators Market Huge Growth and Future Scope 2025 -2032 | Nasanita, SANOSTEC CORP, Splintek, Inc
Internal Nasal Dilators Market Huge Growth and Future Scope 2025 -2032 | Nasanit …
Internal Nasal Dilators Market is estimated to be valued at USD 2.71 Bn in 2025 and is expected to reach USD 4.38 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Internal Nasal Dilators Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key
Paper Cone Market Is Booming Worldwide 2025-2032 | WestRock Company, Clearwater Paper Corporation
Paper Cone Market Is Booming Worldwide 2025-2032 | WestRock Company, Clearwater …
The Global Paper Cone Market is estimated to be valued at USD 9.81 Bn in 2025 and is expected to reach USD 16.27 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.5% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Paper Cone Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth
Captive Power Plant Market Is Booming So Rapidly Growth by 2032 | Ducon Technologies, General Electric, Thermax
Captive Power Plant Market Is Booming So Rapidly Growth by 2032 | Ducon Technolo …
Captive Power Plant Market is estimated to be valued at USD 33.19 Bn in 2025 and is expected to reach USD 78.08 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 13% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Captive Power Plant Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key

All 5 Releases


More Releases for Biosimilar

Interchangeable Biosimilar Humira Market Share Driven by Biologic Therapy Adopti …
Interchangeable Biosimilar Humira Market The global market for Interchangeable Biosimilar Humira was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period View sample report https://reports.valuates.com/request/sample/QYRE-Auto-33I15005/Global_Interchangeable_Biosimilar_Humira_Market_Research_Report_2023 The Interchangeable Biosimilar Humira Market is experiencing significant market growth as healthcare providers and patients increasingly adopt biosimilar therapies for autoimmune and inflammatory conditions. Market trends indicate rising
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of